Review scope
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: A phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Both molecules (0.110 M) stimulated the proliferation of keratinocytes in a dose dependent manner and resulted in changes in epidermal basal cells whose integrins and p63 expression markedly increased
While it isnt a mass-building peptide like MK-677, Tesamorelin shines in cutting phases, recomposition, and longevity-based protocols thanks to its ability to restore GH signaling without spiking hunger or blood glucose
While these studies exist, they are even more preliminary than the gastrointestinal and musculoskeletal research